NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Announces Newly Formed Scientific Advisory Board Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline
SAN FRANCISCO, Jan. 7, 2012 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its...
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
SAN FRANCISCO, Oct. 17, 2011 - Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., to Highlight Company's Technology Platform for the Highly Specific Design and Manufacturing of Novel Protein Therapeutics Sutro Biopharma, a biopharmaceutical company developing...
Study Shows Sutro Biopharma’s Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals Results Published in Biotechnology and Bioengineering Demonstrate that Cell-Free Production of a Biologically Active Human Cytokine Can be Scaled-up to Commercial Manufacturing Levels Study Featured in Journal’s Spotlight Section.
SAN FRANCISCO, May 19, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that a study published in the July issue of Biotechnology and...
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.
San Francisco, CA Jan. 7, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for...
Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics
San Francisco, CA Dec. 8, 2010 - Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed Trevor Hallam, Ph.D., as chief scientific officer...
Sutro Biopharma Secures $36.5 Million in Series C Financing
South San Francisco, CA Nov. 17, 2010 - Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and...
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
South San Francisco, CA (August 20, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced several key appointments to the company’s management. Daniel H. Petree of P2 Partners, LLC has...
Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices — Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production —
South San Francisco, CA (June 9, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, announced today that two additional patents, as well as two patent grant notices, have issued pertaining to...
Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology – Milestone Triggers $15 Million Series B Financing
South San Francisco, CA (March 30, 2009) Sutro Biopharma, Inc., a pioneer in open cell-free synthesis for the discovery and production of proteins, announced today the first ever achievement of therapeutic protein production at 100 L scale using a cell-free synthesis...
William J. Newell Named Chief Executive Officer of Sutro Biopharma – Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer – Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco
South San Francisco, CA (January 12, 2009) Sutro Biopharma, Inc., formerly known as Fundamental Applied Biology, today announced the appointment of William J. Newell as Chief Executive Officer of the company. Daniel S. Gold, Ph.D., the company’s previous CEO becomes...